Asia‑Pacific Vaccine & Immunotherapy Congress 2026 to Convene Global Health Leaders in Singapore

The Asia‑Pacific Vaccine and Immunotherapy Congress (APVIC 2026) will take place May 6–8, 2026 in Singapore, bringing together leading scientists, clinicians, public health experts, and industry professionals to share the latest advances in vaccines and immunotherapy. Hosted at the Matrix in Biopolis, the congress aims to accelerate innovation and collaboration in global health research and clinical practice.

APVIC 2026 is designed as a multidisciplinary forum focused on cutting‑edge developments in vaccine development, immunotherapeutic strategies, clinical trials, and infectious disease research. Delegates can expect a robust program featuring keynote presentations, expert panels, and discussion sessions that explore scientific breakthroughs and real‑world applications of immunization and therapy technologies.

Organised by a scientific committee of prominent researchers and clinicians, the congress offers extensive networking opportunities and strategic sessions aimed at building cross‑sector partnerships. Participants will also have the chance to engage in deep technical discussions on emerging health threats, immuno‑oncology solutions, and pathways to accelerate vaccine deployment across the region.

Singapore’s vibrant biomedical ecosystem and world‑class research infrastructure make it an ideal host city for APVIC 2026, drawing delegates from across Asia and beyond for professional exchange and collaborative innovation.